LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "tp53 mutant" as a keyword



Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer

Sign Up to like & get
recommendations! Published in 2022 at "Advanced Science"

DOI: 10.1002/advs.202105469

Abstract: Targeting the G2/M checkpoint mediator WEE1 has been explored as a novel treatment strategy in ovarian cancer, but mechanisms underlying its efficacy and resistance remains to be understood. Here, it is demonstrated that the WEE1… read more here.

Keywords: tp53 mutant; unfolded protein; ovarian cancer; protein response ... See more keywords

Targeting DNA repair with combined inhibition of NHEJ and MMEJ induces synthetic lethality in TP53-mutant cancers.

Sign Up to like & get
recommendations! Published in 2022 at "Cancer research"

DOI: 10.1158/0008-5472.can-22-1124

Abstract: DNA repair pathway inhibitors are a new class of anti-cancer drugs that are advancing in clinical trials. Peposertib is an inhibitor of DNA-dependent protein kinase (DNA-PK), which is a key driver of non-homologous end-joining (NHEJ).… read more here.

Keywords: dna repair; tp53 mutant; dna; synthetic lethality ... See more keywords

UBE2T-Mediated HP1α Ubiquitination Enhances Nucleolar Function and Promotes the Progression of IDH1/TP53-Mutant Glioma

Sign Up to like & get
recommendations! Published in 2025 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-25-0261

Abstract: Abstract Purpose: High-grade glioma is the most aggressive form of primary brain tumor, characterized by rapid progression and a grim prognosis. The presence of mutations in IDH1 and TP53 is associated with a specific molecular… read more here.

Keywords: tp53 mutant; idh1 tp53; glioma; tp53 ... See more keywords

Abstract 787: Cytosolic TRIM24 characterizes an aggressive subset of ER- PR- and TP53 mutant breast cancer

Sign Up to like & get
recommendations! Published in 2018 at "Cancer Research"

DOI: 10.1158/1538-7445.am2018-787

Abstract: Introduction: Tripartite Motif Containing 24 (TRIM24) is a PhD/Bromodomain containing steroid receptor co-activator that targets p53 for proteosomal degradation, transforms human mammary epithelial cells, and promotes treatment resistance in preclinical models. While bromodomain inhibitors and… read more here.

Keywords: trim24; breast cancer; cancer; tp53 mutant ... See more keywords

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-198057

Abstract: CD47, an immune checkpoint protein expressed on malignant cells, acts as a “don't eat me” signal by binding to signal regulatory protein alpha (SIRPα) on macrophages, enabling cells to evade phagocytosis. High CD47 expression in… read more here.

Keywords: tp53 mutant; ven aza; aml; phagocytosis ... See more keywords

The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-205209

Abstract: Introduction Therapy-related myeloid neoplasms (t-MN) arise from pre-malignant hematopoietic stem and progenitor cells (HSPCs) carrying mutations in leukemia driver genes. Patient outcomes are dismal, especially when harboring mutations in TP53. The molecular mechanisms underlying the… read more here.

Keywords: tp53 mutant; trp53 mutations; therapy; mono biallelic ... See more keywords

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-207718

Abstract: Background: Patients with diffuse large B-cell lymphoma (DLBCL) harboring TP53 mutations (TP53mut DLBCL) face a dismal prognosis and currently lack a standardized treatment regimen. Both ATR (Ataxia Telangiectasia and Rad3-related protein) and ATM (Ataxia Telangiectasia… read more here.

Keywords: dlbcl; tp53 mutant; mutant; yl0712 ... See more keywords
Photo by niaid from unsplash

Inhibition of DOCK1 prevents the clonal expansion of high-risk TP53-mutant clonal hematopoiesis induced by genotoxic stressors.

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-631

Abstract: Background: TP53-mutant clonal hematopoiesis (CH) is prevalent in populations that received genotoxic cancer therapy and is associated with elevated risk for therapy-related myeloid neoplasms. As TP53 mutations primarily act through loss of function, it has… read more here.

Keywords: tp53 mutant; hspcs; culture; clonal expansion ... See more keywords

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Sign Up to like & get
recommendations! Published in 2020 at "Blood"

DOI: 10.1182/blood.2020006158

Abstract: Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The precise… read more here.

Keywords: myelodysplastic syndromes; secondary aml; tp53 mutant; tp53 mutations ... See more keywords
Photo from wikipedia

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

Sign Up to like & get
recommendations! Published in 2021 at "Blood advances"

DOI: 10.1182/bloodadvances.2020003300

Abstract: Mature natural killer (NK) cell neoplasms are rare but very aggressive types of cancers. With currently available treatments, they have a very poor prognosis and, as such, are an example of group of cancers in… read more here.

Keywords: cell neoplasms; inhibitor; drug; tp53 mutant ... See more keywords

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology

Sign Up to like & get
recommendations! Published in 2022 at "Blood Advances"

DOI: 10.1182/bloodadvances.2021006580

Abstract: A recent article in Blood Advances by Short et al 1 entitled “ Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia, ” had very interesting conclusions that… read more here.

Keywords: tp53 mutant; acute myeloid; myeloid leukemia; hematology ... See more keywords